MedWorm: Abilify

Aripiprazole: A Review of its Use in the Management of Schizophrenia in Adults

CNS Drugs — Mon, 06 Feb 2012 01:22:15 +0100

(Source: CNS Drugs)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Aripiprazole may be free from tachyphylaxis: Preliminary findings

Psychiatry and Clinical Neurosciences — Thu, 02 Feb 2012 05:00:00 +0100

Loss of antipsychotic efficacy (tachyphylaxis), possibly linked to an increase in D2 receptor number and sensitivity, is a significant impediment to treatment in chronic schizophrenia patients. Animal studies, however, suggest that aripiprazole may be free from tachyphylaxis. The aim of the present study was to investigate this hypothesis. In this preliminary study, aripiprazole‐treated patients were retrospectively investigated for the presence or absence of tachyphylaxis. Clinical Global Impression‐Improvement (CGI‐I) scores did not significantly change and there was no significant association of CGI scores with fixed dose duration. This suggests that aripiprazole may be free from tachyphylaxis. (Source: Psychiatry and Clinical Neurosciences)

The Brown University Child and Adolescent Psychopharmacology Update — Sat, 28 Jan 2012 19:11:52 +0100

AbstractNew AACAP Practice Parameter for OCDPresence of Disruptive Behaviors With Bipolar Predicts Drug ResponsePediatric Bipolar Disorder: Aripiprazole Tested as Maintenance TreatmentLisdexamfetamine Improves ADHD Symptoms/Functioning in College StudentsExpert Recommendations on Treating Aggressive YouthHigh Antipsychotic Rates in Foster CareOpen‐Label Study of Citalopram in Hospitalized TeensNo Increased Risk of Serious Heart Disease With ADHD Drugs in Young or Older AdultsCognitive Function in Adolescent Schizophrenia Following ECTImipramine for Risperidone‐Induced EnuresisSSRIs in Pregnancy: No Change in RecommendationsRecommendations Unchanged on ADHD DrugsNew Approvals (Source: The Brown University Child and Adolescent Psychopharmacology Update)

A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy among Depressed Outpatients with Inadequate Response to Prior Antidepressant Therapy (ADAPT-A Study)

Psychotherapy and Psychosomatics — Tue, 24 Jan 2012 23:00:00 +0100

Psychother Psychosom 2012;81:87–97 (DOI:10.1159/000332050) (Source: Psychotherapy and Psychosomatics)

ABILIFY (Aripiprazole) Tablet [PD-Rx Pharmaceuticals, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 19 Jan 2012 05:00:00 +0100

Updated Date: Jan 19, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

ABILIFY (Aripiprazole) Tablet [H.J. Harkins Company, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 18 Jan 2012 05:00:00 +0100

Updated Date: Jan 18, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Determination of aripiprazole in rat plasma and brain using ultra-performance liquid chromatography/electrospray ionization tandem mass spectrometry.

Biomedical Chromatography : BMC — Wed, 18 Jan 2012 05:00:00 +0100

Authors: Liang F, Terry AV, Bartlett MG Abstract Aripiprazole is an important antipsychotic drug. A simple, sensitive and rapid ultra-performance liquid chromatography/electrospray ionization tandem mass spectrometry (UPLC-ESI-MS/MS) method was developed and validated for the simultaneous quantification of this compound in rat plasma and brain homogenate. The analyte was extracted from rat plasma and brain homogenate using a weak cation exchange mixed-mode resin-based solid phase extraction. The compound was separated on an Agilent Eclipse Plus C(18) (2.1 × 50 mm, 1.8 µm) column using a mobile phase of (A) 0.1% formic acid aqueous and (B) acetonitrile with gradient elution. The analyte was detected in positive ion mode using multiple reaction monitoring. The method was va...

Aripiprazole: Pathological gambling: 3 case reports

Reactions — Tue, 17 Jan 2012 19:08:18 +0100

(Source: Reactions)

Treatments for Methamphetamine Abuse: A Literature Review for the Clinician

Journal of Pharmacy Practice — Tue, 17 Jan 2012 05:00:00 +0100

The objective of this article is to critically review the literature of METH treatment options. Preclinical research and human research with compounds not yet available commercially in the United States will not be included. A literature review was conducted for research on pharmacological treatments for METH use and addiction. Trial information on the use of sertraline, bupropion, mirtazapine, modafinil, dextroamphetamine, ondansetron, risperidone, aripiprazole, baclofen, and gabapentin was reviewed. Aripiprazole trials appeared in the reviewed literature more frequently than the other medications. Based on the findings of this review, no single medication demonstrated consistent efficacy and each trial contained a variety of methodological limitations. (Source: Journal of Pharmacy Practi...

In vitro effect of antipsychotics on brain energy metabolism parameters in the brain of rats

Acta Neuropsychiatrica — Thu, 12 Jan 2012 05:00:00 +0100

Conclusion: In this context, if the hypothesis that metabolism impairment is involved in the pathophysiology of neuropsychiatric disorders is correct and these results also occur in vivo, we suggest that olanzapine may reverse a possible diminution of metabolism. (Source: Acta Neuropsychiatrica)

Striatal and extrastriatal dopamine D2 receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [11C]raclopride and [11C]FLB457

Psychopharmacology — Wed, 11 Jan 2012 17:55:37 +0100

Conclusions In the present study, preferential extrastriatal dopamine D2 receptor occupancy by aripiprazole was not observed. Our data suggest partial agonism at dopamine D2 receptors is the most likely explanation for the minimal risk of extrapyramidal side effects in the treatment by aripiprazole. Content Type Journal ArticleCategory Original InvestigationPages 1-8DOI 10.1007/s00213-011-2633-5Authors Keisuke Takahata, Clinical Neuroimaging Team, Molecular Neuroimaging Program, Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, JapanHiroshi Ito, Clinical Neuroimaging Team, Molecular Neuroimaging Program, Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, JapanHarumasa Takano, Clinical Neuroimaging Team, Molecular ...

MedWorm Sponsor Message: Find the best January Sales in the UK.

ABILIFY (Aripiprazole) Tablet [Physicians Total Care, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 06 Jan 2012 05:00:00 +0100

Updated Date: Jan 6, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Intermittent aripiprazole for schizophrenia

Schizophrenia Research — Tue, 03 Jan 2012 05:00:00 +0100

Medication nonadherence is associated with poorer outcome in schizophrenia. A 1–10day gap in taking medication is associated with a 2-fold increase in risk of hospitalization (). As the gap increases to more than 30days the risk quadruples (). Discontinuation of medication increases the risk of relapse nearly 5 fold (). Approximately one third of patients with schizophrenia are nonadherent to pharmacologic treatment (). (Source: Schizophrenia Research)

Aripiprazole: A Review of its Use in the Management of Mania in Adults with Bipolar I Disorder

Drugs — Wed, 28 Dec 2011 10:06:25 +0100

(Source: Drugs)

Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons

Schizophrenia Bulletin — Fri, 23 Dec 2011 05:00:00 +0100

Conclusions: Our meta-analysis demonstrates that there are differences between the SGAs in their ability to induce EPS that clinicians consider warrant treatment with antimuscarinic drugs. Even though the differences were relatively small, they might be important for individual patients and should be taken into account in drug choice. (Source: Schizophrenia Bulletin)

Aripiprazole may be effective maintenance in young children with bipolar disorder

Modern Medicine — Fri, 16 Dec 2011 05:00:00 +0100

NEW YORK (Reuters Health) - If young children with bipolar disorder can be stabilized with aripiprazole therapy, they might continue to benefit from maintenance treatment, researchers say. (Source: Modern Medicine)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose?

BMC Psychiatry - Latest articles — Thu, 15 Dec 2011 05:00:00 +0100

Conclusions: In this large multi-site epidemiologic study, within each drug-specific stratum, the risk of diabetes for persons exposed to olanzapine, risperidone, and quetiapine was dose-dependent and elevated at therapeutic doses. In contrast, in aripiprazole-specific and ziprasidone-specific stratum, these newer agents were not associated with an increased risk of diabetes and dose-dependent relationships were not apparent. Although, these estimates should be interpreted with caution as they are imprecise due to small numbers. (Source: BMC Psychiatry - Latest articles)

ABILIFY (Aripiprazole) Tablet [Lake Erie Medical Surgical Supply DBA Quality Care Products LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Tue, 13 Dec 2011 05:00:00 +0100

Updated Date: Dec 13, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

[Aripiprazole augmentation treatment in treatment resistant bipolar depression: two patient reports].

Turkish Journal of Psychiatry — Mon, 12 Dec 2011 13:54:02 +0100

In this report, treatment of refractory bipolar depression and the efficacy of aripiprazole augmentation treatment in bipolar depression are discussed through two patients in depressive episode who remitted with aripiprazole augmentation. PMID: 22143953 [PubMed - in process] (Source: Turkish Journal of Psychiatry)

Discriminative stimulus, subject-rated and cardiovascular effects of cocaine alone and in combination with aripiprazole in humans

Journal of Psychopharmacology — Mon, 12 Dec 2011 05:00:00 +0100

Aripiprazole is a dopamine D2 receptor partial agonist undergoing evaluation as a pharmacotherapy for stimulant-use disorders. Acutely administered aripiprazole attenuates the discriminative stimulus and other behavioral effects of d-amphetamine in humans; however, whether aripiprazole attenuates the effects of more commonly abused stimulants is unknown. The aim of this experiment was to assess the discriminative stimulus, subject-rated and cardiovascular effects of oral cocaine alone and following acute administration of aripiprazole in humans. Eight cocaine-dependent subjects learned to discriminate 150 mg cocaine from placebo. After acquiring the discrimination, the effects of cocaine (0, 25, 50, 100 and 200 mg) administered alone and in combination with aripiprazole (15 mg) were determ...

Reinforcement Learning and Gilles de la Tourette Syndrome: Dissociation of Clinical Phenotypes and Pharmacological Treatments [Original Article]

Archives of General Psychiatry — Mon, 05 Dec 2011 05:00:00 +0100

Conclusions These results support the hypothesized correspondence between clinical phenotypes and frontal cortex–basal ganglia circuits. Antipsychotic treatment effects comply with formal conceptions that dopamine serves as a teaching signal for reinforcement learning. Furthermore, we suggest that, unlike typical antipsychotics, aripiprazole may preserve reward sensitivity and hence avoid blunting motivational drives. (Source: Archives of General Psychiatry)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Aripiprazole plus divalproex for recently manic or mixed patients with bipolar I disorder: a 6‐month, randomized, placebo‐controlled, double‐blind maintenance trial

Human Psychopharmacology: Clinical and Experimental — Fri, 02 Dec 2011 05:00:00 +0100

ConclusionsIn this study, relapse of mood episode occurred fewer and later for aripiprazole with divalproex treatment than divalproex monotherapy, but the differences were not statistically significant. Copyright © 2011 John Wiley & Sons, Ltd. (Source: Human Psychopharmacology: Clinical and Experimental)

Aripiprazole: Delayed neurotoxicity in pediatric patients: 4 case reports

Reactions — Thu, 01 Dec 2011 07:29:01 +0100

(Source: Reactions)

Aripiprazole: Tardive dyskinesia and tremor: case report

Reactions — Thu, 01 Dec 2011 07:29:01 +0100

(Source: Reactions)

Aripiprazole altered plasma levels of brain‐derived neurotrophic factor and catecholamine metabolites in first‐episode untreated Japanese schizophrenia patients

Human Psychopharmacology: Clinical and Experimental — Thu, 01 Dec 2011 05:00:00 +0100

ConclusionsTo the best of our knowledge, this is the first report showing that aripiprazole increases plasma BDNF levels in first‐episode untreated schizophrenia patients. Furthermore, the BDNF Val66Met polymorphism was independent of the response to aripiprazole. Copyright © 2011 John Wiley & Sons, Ltd. (Source: Human Psychopharmacology: Clinical and Experimental)

Adjunctive aripiprazole for depression: predictive value of early assessment.

The American Journal of Managed Care — Thu, 01 Dec 2011 05:00:00 +0100

Conclusions: Week 2 was a clinically meaningful time point to identify early improvers, and lack of improvement early in treatment was a highly significant predictor of lack of later remission. Early assessment of changes in symptoms could prove useful in clinical practice and more appropriately target healthcare costs. PMID: 22216750 [PubMed - in process] (Source: The American Journal of Managed Care)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

An open trial of aripiprazole for the treatment of delirium in hospitalized cancer patients.

Palliative and Supportive Care — Wed, 23 Nov 2011 17:50:04 +0100

Authors: Boettger S, Breitbart W Abstract Objective:The purpose of this study was to examine the efficacy and safety of aripiprazole in the treatment of delirium in hospitalized cancer patients, and to examine differential responses based on delirium subtypes.Method:We conducted an analysis of 21 hospitalized cancer patients at Memorial Sloan-Kettering Cancer Center (MSKCC) who had been evaluated and treated for delirium with aripiprazole, using an MSKCC Institutional Review Board (IRB) approved Clinical Delirium Database. Measures used were the Memorial Delirium Assessment Scale (MDAS), the Karnofsky Scale of Performance Status (KPS), and side effect rating at baseline (T1), 2-3 days (T2), and 4-7 days (T3). All measurements were integrated into the routine clinical care of patien...

Schizophrenia substance set for FDA review

Pharmacy Europe — Tue, 22 Nov 2011 12:47:00 +0100

Aripiprazole depot formulation for treatment of adult patients accepted by US body (Source: Pharmacy Europe)

Delusional Infestation in a Patient with Renal Failure, Metabolic Syndrome, and Chronic Cerebrovascular Disease Treated with Aripiprazole: A Case Report

Advances in Urology — Thu, 17 Nov 2011 16:00:47 +0100

We report a case of a 72-year-old patient affected by delusional infestation associated with severe renal failure, metabolic syndrome, hypertensive cardiopathy, and chronic cerebrovascular disease. (Source: Advances in Urology)

Aripiprazole: Atypical neuroleptic malignant syndrome: case report

Reactions — Wed, 16 Nov 2011 21:59:42 +0100

(Source: Reactions)

Aripiprazole: Hypersexuality: case report

Reactions — Wed, 16 Nov 2011 21:59:42 +0100

(Source: Reactions)

MedWorm Sponsor Message: Find the best January Sales in the UK.

ABILIFY (Aripiprazole) Tablet [Lake Erie Medical Surgical Supply DBA Quality Care Products LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 16 Nov 2011 05:00:00 +0100

Updated Date: Nov 16, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Sign Historic Agreement to Deliver Innovative Medicines with Focus on Psychiatric Disorders Worldwide

Drugs.com - Pharma News — Fri, 11 Nov 2011 12:45:59 +0100

ˆ’ Starting with a USD 1.8 billion agreement to co-develop and co-commercialize aripiprazole depot formulation and OPC-34712, two companies with a rich CNS heritage form one of the largest global alliances to focus on delivering up to... (Source: Drugs.com - Pharma News)

Visible spectrophotometric method for the determination of aripiprazole in tablets

Indian Journal of Pharmaceutical Sciences — Fri, 11 Nov 2011 05:00:00 +0100

R Jain, SK Kashaw, Rishab Jain, P Mishra, DV KohliIndian Journal of Pharmaceutical Sciences 2011 73(1):74-76A simple, accurate and economic spectrophotometric method for the determination of aripiprazole in tablet formulation is proposed. In the present method acidic solution of the aripiprazole formed colored ion-association complexes with bromocresol green, soluble in chloroform. Yellowish orange chromogen showed λmax at 414 nm and obeyed Beer's law in the concentration range of 10-60 μg/ml. Statistical analysis and recovery studies validated the method. The proposed method is rapid, precise and accurate and can be applied for the routine estimation of aripiprazole in the laboratory. (Source: Indian Journal of Pharmaceutical Sciences)

Memory disorders associated with consumption of drugs: updating through a case/noncase study in the French PharmacoVigilance Database

British Journal of Clinical Pharmacology — Thu, 10 Nov 2011 07:45:51 +0100

CONCLUSIONS Our study confirmed an association between memory disorders and some drugs, such as benzodiazepines and anticonvulsants. However, other drugs, such as benzodiazepine‐like hypnotics, newer anticonvulsants, serotonin reuptake inhibitor antidepressants, isotretinoin and ciclosporin were significantly associated with memory disorders, although this was not described or poorly described in the literature.Taking account of the limits of this study in the FPVD (under‐reporting, notoriety bias etc.), the case/noncase method allows assessment and detection of associations between exposure to drugs and a specific adverse drug reaction, such as memory disorders, and could thus generate signals and orientate us to further prospective studies to confirm such associations. (Source: Briti...

Discovery of {beta}-Arrestin-Biased Dopamine D2 Ligands for Probing Signal Transduction Pathways Essential for Antipsychotic Efficacy [Chemistry]

Proceedings of the National Academy of Sciences — Tue, 08 Nov 2011 05:00:00 +0100

Elucidating the key signal transduction pathways essential for both antipsychotic efficacy and side-effect profiles is essential for developing safer and more effective therapies. Recent work has highlighted noncanonical modes of dopamine D2 receptor (D2R) signaling via β-arrestins as being important for the therapeutic actions of both antipsychotic and antimanic agents. We thus sought to create unique D2R agonists that display signaling bias via β-arrestin–ergic signaling. Through a robust diversity-oriented modification of the scaffold represented by aripiprazole (1), we discovered UNC9975 (2), UNC0006 (3), and UNC9994 (4) as unprecedented β-arrestin–biased D2R ligands. These compounds also represent unprecedented β-arrestin–biased ligands for a Gi-coupled G protein–coupled r...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Aripiprazole: Hyponatraemia: case report

Reactions — Wed, 26 Oct 2011 13:05:17 +0100

(Source: Reactions)

Improvement of tardive dyskinesia and dystonia associated with aripiprazole following a switch to quetiapine: case report and review of the literature

Journal of Clinical Pharmacy and Therapeutics — Mon, 24 Oct 2011 04:00:00 +0100

Conclusion: There were several previous case reports on dyskinesia and dystonia associated with aripiprazole medication. The risk factors for tardive dyskinesia include older age and female sex. However, our case was a male patient who was younger compared with the previous cases and so should have been less at risk for dyskinesia in comparison with the previous cases. The effects of aripiprazole can include tardive movement disorders. Dyskinesia, dystonia and psychotic symptoms were improved with relatively small dose of quetiapine in this case. Whether some second‐generation antipsychotics are more effective than others in the treatment of tardive dyskinesia remains unclear. (Source: Journal of Clinical Pharmacy and Therapeutics)

ABILIFY (Aripiprazole) Tablet [Cardinal Health]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 19 Oct 2011 05:00:00 +0100

Updated Date: Oct 19, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Abilify 7.5 mg/ml solution for injection (intramuscular) (Aripriprazole)- Revised SPC

NeLM - SPC Changes — Wed, 19 Oct 2011 04:00:00 +0100

Source: eMC (electronic Medicines Compendium) Area: Other Library Updates > SPC Changes There have been significant updates to several sections of the SPC, the following sections have all been updated: Change to section 4.6 - Pregnancy and Lactation Change to section 4.8 - Undesirable Effects Change to section 10 date of revision of the text Please refer to SPC link below for full information on all changes. (Source: NeLM - SPC Changes)

[Rapid tranquillisation; review of the literature and recommendations].

Tijdschrift voor Psychiatrie — Fri, 14 Oct 2011 17:25:04 +0100

Authors: Bak M, van Os J, Marcelis M Abstract summary background In The Netherlands, no guidelines exist for rapid tranquillisation in the contextof acute agitation, excitementor aggression secondarytoapsychiatric disorder. aim To generate an overview of medication regimes suitable for rapid tranquillisation. method Aliterature search was conducted focussing on the effect of medical interventions in acute excitement, agitation or aggression. Primary outcome measurements were tranquillity, being calm, sedation, or asleep within two hours. Secondary outcome measures were frequency of re-administrat...

MedWorm Sponsor Message: Find the best January Sales in the UK.

Aripiprazole in Children and Adolescents with Conduct Disorder: A Single-Center, Open-Label Study

Pharmacopsychiatry — Wed, 12 Oct 2011 04:00:00 +0100

PharmacopsychiatryDOI: 10.1055/s-0031-1286348The aim of this study was to determine the effectiveness and safety of aripiprazole in children and adolescents with both attention-deficit/hyperactivity disorder (ADHD) and conduct disorder (CD).20 children and adolescents, ranging in age from 6–16 years, participated in a single-center, open-label study (19 to completion). We began treating patients with 2.5 mg of aripiprazole in an open-label fashion for 8 weeks. Outcome measures included the Turgay DSM-IV-based child and adolescent behavior disorders screening and rating scale (T-DSM-IV), the clinical global impressions-severity and improvement scales (CGI-S and CGI-I), the child behavior checklist (CBCL), the teachers report form (TRF) and the extrapyramidal symptom rating scale (ES...

Aripiprazole cost effective for teens with schizophrenia

PharmacoEconomics and Outcomes News — Mon, 10 Oct 2011 03:06:48 +0100

(Source: PharmacoEconomics and Outcomes News)

[Articles] Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis

LANCET — Sat, 08 Oct 2011 04:00:00 +0100

SummaryBackgroundConventional meta-analyses have shown inconsistent results for efficacy of pharmacological treatments for acute mania. We did a multiple-treatments meta-analysis, which accounted for both direct and indirect comparisons, to assess the effects of all antimanic drugs.MethodsWe systematically reviewed 68 randomised controlled trials (16 073 participants) from Jan 1, 1980, to Nov 25, 2010, which compared any of the following pharmacological drugs at therapeutic dose range for the treatment of acute mania in adults: aripiprazole, asenapine, carbamazepine, valproate, gabapentin, haloperidol, lamotrigine, lithium, olanzapine, quetiapine, risperidone, topiramate, and ziprasidone. (Source: LANCET)

An Efficient Synthesis of Aripiprazole, Buspirone and NAN‐190 by the Reductive Alkylation of Amines Procedure

Archiv der Pharmazie — Wed, 05 Oct 2011 04:00:00 +0100

AbstractThe reductive alkylation of amines procedure was applied for the synthesis of aripiprazole 1a, buspirone 1b, and NAN‐190 1c.The reductive alkylation of amines procedure has been applied for the synthesis of aripiprazole 1a, buspirone 1b, and NAN‐190 1c. (Source: Archiv der Pharmazie)

Effectiveness and safety of antipsychotics in early onset psychoses: A long-term comparison

Psychiatry Research — Wed, 05 Oct 2011 03:45:58 +0100

Abstract: The effectiveness and safety of various antipsychotics was evaluated in a long-term study on 47 patients, 29 with schizophrenia and 18 with schizoaffective disorder, aged 10 to 17years (mean 15.5) at onset. Follow-up ranged from 3years (all 47 patients) to 11years (19 patients). Data were collected on the following antipsychotics: haloperidol, risperidone, olanzapine, quetiapine, aripiprazole and clozapine. Cases with positive response were significantly more frequent with clozapine as compared to haloperidol, risperidone and olanzapine. Risperidone was significantly better than haloperidol at the 3-year follow-up. A comparison of the degree of clinical improvement evaluated with PANSS and CGI in patients treated with drugs in subsequent periods showed clozapine led to significan...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Aripiprazole/loxapine: Tremor, sedation and sialorrhoea: 2 case reports

Reactions — Mon, 03 Oct 2011 06:00:13 +0100

(Source: Reactions)

Aripiprazole/olanzapine/risperidone: Catatonia and neuroleptic malignant syndrome: case report

Reactions — Mon, 03 Oct 2011 06:00:13 +0100

(Source: Reactions)

Aripiprazole monotherapy in the treatment of vascular parkinsonism

Psychiatry and Clinical Neurosciences — Sat, 01 Oct 2011 04:00:00 +0100

(Source: Psychiatry and Clinical Neurosciences)

Meta-analysis: Efficacy and comparative effectiveness of atypical antipsychotics for off-label uses

NeLM - News — Wed, 28 Sep 2011 04:00:00 +0100

Source: JAMA Area: News The Journal of the American Medical Association has featured a meta-analysis of trials assessing the efficacy and safety of atypical antipsychotic medications for use in conditions lacking approval for labeling and marketing by the US Food and Drug Administration. Controlled trials comparing an atypical antipsychotic (risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, asenapine, iloperidone, or paliperidone) with placebo, another atypical antipsychotic medication, or other pharmacotherapy for adult off-label conditions were included to assess efficacy. Furthermore, observational studies with sample sizes of greater than 1000 patients were included for the safety analysis. A total of 162 citations met inclusion criteria for the eff...

Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in Adults: A Systematic Review and Meta-analysis [Clinical Review]

JAMA — Tue, 27 Sep 2011 04:00:00 +0100

Conclusions Benefits and harms vary among atypical antipsychotic medications for off-label use. For global behavioral symptom scores associated with dementia in elderly patients, small but statistically significant benefits were observed for aripiprazole, olanzapine, and risperidone. Quetiapine was associated with benefits in the treatment of generalized anxiety disorder, and risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; however, adverse events were common. (Source: JAMA)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Coming Soon to an Entrepreneur Near You: The Cyclothymic Personality

Psychology Today Personality Center — Mon, 26 Sep 2011 20:04:06 +0100

When you’re too ready for prime time, not quite ready for lithium and then pity the poor spouse or COO who tries to keep you on the rails. Primary Topic: Personality read more (Source: Psychology Today Personality Center)

Improvement of Oral Dyskinesia After Switching From Aripiprazole to Paliperidone: A Case Report [LETTERS TO THE EDITOR]

J Neuropsychiatry Clin Neurosci — Fri, 23 Sep 2011 04:00:00 +0100

(Source: J Neuropsychiatry Clin Neurosci)

Aripiprazole-Associated Rhabdomyolysis in a Patient With Schizophrenia [LETTERS TO THE EDITOR]

J Neuropsychiatry Clin Neurosci — Fri, 23 Sep 2011 04:00:00 +0100

(Source: J Neuropsychiatry Clin Neurosci)

Aripiprazole: Persistent hiccups: case report

Reactions — Thu, 22 Sep 2011 07:55:36 +0100

(Source: Reactions)

Geissoschizine methyl ether has third-generation antipsychotic-like actions at the dopamine and serotonin receptors.

European Journal of Pharmacology — Wed, 21 Sep 2011 04:00:00 +0100

Authors: Ueda T, Ugawa S, Ishida Y, Shimada S Abstract Aripiprazole has made a significant contribution to the treatment of schizophrenia and related disorders. It has improved its safety and tolerability profiles, and these effects have been attributed to its pharmacological profile at the serotonin 5-HT and dopamine D(2) receptors. To discover compounds that have a similar pharmacological profile, we introduced a generic single-cell-based calcium imaging assay that standardizes the readouts from various assays used in previous studies on aripiprazole. In the present assay, the efficacy and potency of known ligands of serotonin 5-HT(1A), 5-HT(2A), 5-HT(2C), 5-HT(7) and dopamine D(2L) receptors were comparable to those found in previous studies using a variety of readouts. The deve...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

You Are Not "Chemically Imbalanced"!

Psychology Today Addiction Center — Tue, 20 Sep 2011 10:48:52 +0100

I just read such a depressing book that it would make just about anyone need an antidepressant if it wasn’t for the fact that the book itself debunks the entire psychopharmacological industry in such a convincing way that it would be maddening if it weren’t so saddening. Primary Topic: Psychiatry read more (Source: Psychology Today Addiction Center)

Aripiprazole: Enuresis: case report

Reactions — Sun, 18 Sep 2011 23:35:47 +0100

(Source: Reactions)

Psychiatric Medication Minimization Strategies: Part I

Psychology Today Parenting Center — Sat, 17 Sep 2011 07:20:52 +0100

No one wants to take psychotropic medication, much less request a child or other family member take them. LIke it or not, sometimes medication is necessary and even protective. But certain medications--espcially the antipsychotics (Risperdal, Seroquel, Geodon, Abilify, Haldol)--are worth some extra attention when it comes to dosing, especially when taken over the long term. Primary Topic: Parenting read more (Source: Psychology Today Parenting Center)

Addition of Aripiprazole to the Clozapine May Be Useful in Reducing Anxiety in Treatment-Resistant Schizophrenia

Comparative and Functional Genomics — Wed, 14 Sep 2011 07:40:24 +0100

There exist many case reports and studies on the antipsychotic augmentation by aripirazole in partial responders to clozapine, the most seem to be finding a slight difference in the PANSS and CGI scores after the aripirazole addition. The results of our report are compatible with those of other studies but, we have found a considerable antianxiety action in both of the cases. The 5HT1A agonism of aripirazole could be hypothesized as mechanism contributing to this effect. (Source: Comparative and Functional Genomics)

A prospective, multicentre, open-label study to evaluate the effectiveness of aripiprazole in the treatment of a broad range of patients with schizophrenia.

European Psychiatry — Tue, 13 Sep 2011 04:00:00 +0100

CONCLUSION: Aripiprazole was effective in a broad range of patients with schizophrenia. PMID: 21920707 [PubMed - as supplied by publisher] (Source: European Psychiatry)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Clinical usefulness of second-generation antipsychotics in treating children and adolescents diagnosed with bipolar or schizophrenic disorders.

Paediatric Drugs — Sat, 10 Sep 2011 17:46:54 +0100

Authors: Gentile S Abstract The onset of severe, chronic or recurrent psychiatric illnesses, such as schizophrenia-spectrum and bipolar disorders, is a dramatic clinical event often detectable during adolescence and even in childhood. At any age, pharmacotherapy, along with enhancement of social skills and family support, is the mainstay for the management of such disorders. The aim of this review is to critically analyze findings from randomized controlled trials (RCTs) that have investigated the clinical utility of second-generation antipsychotics (SGAs) for the treatment of early-onset schizophrenia and bipolar disorders. Eighteen studies were considered, all of which were unfortunately impaired by methodologic limitations, such as the paucity of long-term data and lack of a thr...

Aripiprazole Associated With Acute Dystonia, Akathisia, and Parkinsonism in a Single Patient.

The Journal of Clinical Pharmacology — Thu, 08 Sep 2011 04:00:00 +0100

Authors: Saddichha S, Kumar R, Babu GN, Chandra P PMID: 21903892 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Pharmacology)

Adherence, persistence of use, and costs associated with second-generation antipsychotics for bipolar disorder

NeLM - Mental Health — Wed, 07 Sep 2011 04:00:00 +0100

Source: Psychiatric Services Area: Evidence > Medicines Management > References Objective: A retrospective study using US Medicaid claims identified patients with bipolar disorder for whom oral second-generation antipsychotics were prescribed and compared rates of adherence, persistence of use and costs across five groups of patients taking aripiprazole, olanzapine, quetiapine, risperidone or ziprasidone. Methods: Medicaid claims data for 2446 bipolar patients were analysed from eight US states. The 18-month observation period included the 6 months before and the 12 months after the index prescription date. Adherence was defined as a medication possession ratio above 80%. Persistence of use was measured by the number of days of medication therapy before a 30-day g...

Aripiprazole: Dizziness: case report

Reactions — Sun, 04 Sep 2011 16:16:09 +0100

(Source: Reactions)

Aripiprazole: Tardive dyskinesia: case report

Reactions — Sun, 04 Sep 2011 16:16:09 +0100

(Source: Reactions)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

A Randomized Trial Examining the Effectiveness of Switching From Olanzapine, Quetiapine, or Risperidone to Aripiprazole to Reduce Metabolic Risk: Comparison of Antipsychotics for Metabolic Problems (CAMP) [Articles]

Am J Psychiatry — Thu, 01 Sep 2011 23:00:00 +0100

Conclusions: Switching to aripiprazole led to improvement of non-HDL cholesterol levels and other metabolic parameters. Rates of efficacy failure were similar between groups, but switching to aripiprazole was associated with a higher rate of treatment discontinuation. In the context of close clinical monitoring, switching from an antipsychotic with high metabolic risk to one with lower risk to improve metabolic parameters is an effective strategy. (Source: Am J Psychiatry)

Adherence, Persistence of Use, and Costs Associated With Second-Generation Antipsychotics for Bipolar Disorder [Articles]

Psychiatr Serv — Wed, 31 Aug 2011 23:00:00 +0100

Conclusions: Among patients in a sizeable Medicaid cohort for whom a second-generation antipsychotic medication was prescribed, less than half had a clinically recommended dose, and less than two-thirds with a clinically recommended dose were adherent to the medication, confirming that many patients with bipolar disorder do not receive clinically recommended doses of second-generation antipsychotics. (Psychiatric Services 62:1032–1040, 2011) (Source: Psychiatr Serv)

[Priapism due to a Single Dose of Quetiapine: A Case Report].

Turkish Journal of Psychiatry — Tue, 30 Aug 2011 22:36:06 +0100

Authors: Torun F, Yılmaz E, Gümüş E Abstract Priapism is characterized by a prolonged and painful erection in the absence of sexual desire and arousal. Priapism is a rare and serious side effect of psychotropic drugs, and is thought to be attributable to blockage of alpha-1 adrenergic receptors in the corpus cavernosum. Although priapism is commonly associated with typical antipsychotics, there are some (but not many) case reports of priapism due to atypical antipsychotics. This side effect has been reported in patients taking ziprasidone, risperidone, clozapine, quetiapine, aripiprazole, and olanzapine. Not all antipsychotics bind to alpha-1 adrenergic receptors with the same intensity; as compared to other antipsychotics, quetiapine has an intermediate affinity. Priapism coul...

Aripiprazole in the Treatment of Irritability Associated with Autistic Disorder in Paediatric Patients: Profile Report

CNS Drugs — Tue, 30 Aug 2011 17:57:37 +0100

(Source: CNS Drugs)

Aripiprazole versus placebo for schizophrenia

NeLM - Mental Health — Mon, 29 Aug 2011 23:00:00 +0100

Source: Cochrane Area: Evidence > Drug Specific Reviews Background First generation 'typical' antipsychotics such as chlorpromazine and haloperidol have been the mainstay of treatment up until the introduction of the second generation 'atypical' antipsychotics such as risperidone and olanzapine. Typical and atypical antipsychotics do provide a treatment response for most people with schizophrenia, whether a reduction in psychotic episodes or a lessening in the severity of their illness. However, a proportion of people still do not respond adequately to antipsychotic medication. Additionally, atypical and especially typical antipsychotics are associated with serious adverse effects, which can often compromise compliance with medication and therefore increase the incidences of relapse. In...

MedWorm Sponsor Message: Find the best January Sales in the UK.

Aripiprazole: Parkinsonism in a child: case report

Reactions — Mon, 29 Aug 2011 14:09:06 +0100

(Source: Reactions)

Aripiprazole monotherapy in the treatment of bipolar disorder: A meta-analysis

Journal of Affective Disorders — Wed, 24 Aug 2011 14:27:27 +0100

Discussion: The current meta-analysis supports the usefulness of aripiprazole during all phases of bipolar illness. Its effect against acute bipolar depression is weak and the efficacy during the maintenance phase is proven only against new manic episodes in patients with an index manic episode who had previously responded to aripiprazole during the acute phase. (Source: Journal of Affective Disorders)

Aripiprazole versus placebo for schizophrenia.

Cochrane Database of Systematic Reviews — Sat, 20 Aug 2011 17:00:05 +0100

CONCLUSIONS: Aripiprazole may be effective for the treatment of schizophrenia. Aripiprazole has a lower risk of raised prolactin and prolongation of the QTc interval. Clearly reported pragmatic short-, medium- and long-term randomised controlled trials should be undertaken to determine its position in everyday clinical practice. PMID: 21833956 [PubMed - in process] (Source: Cochrane Database of Systematic Reviews)

Neurobehavioral and genotoxic parameters of antipsychotic agent aripiprazole in mice.

Acta Pharmacologica Sinica — Sun, 14 Aug 2011 23:00:00 +0100

Conclusion:Aripiprazole improved memory, but could impair motor activities in mice. The drug increased DNA damage in blood, but did not show mutagenic effects, suggesting that it might affect long-term genomic stability. PMID: 21841809 [PubMed - as supplied by publisher] (Source: Acta Pharmacologica Sinica)

Aripiprazole Augmentation in the Treatment of Military-Related PTSD With Major DepressionAripiprazole Augmentation in the Treatment of Military-Related PTSD With Major Depression

Medscape Today Headlines — Thu, 11 Aug 2011 13:04:38 +0100

Can the addition of the novel antipsychotic aripiprazole benefit veterans with military-related PTSD and comorbid depression which has been resistant to standard treatments? BMC Psychiatry (Source: Medscape Today Headlines)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Intent-to-Treat Analysis of Health Care Expenditures of Patients Treated With Atypical Antipsychotics as Adjunctive Therapy in Depression.

Clinical Therapeutics — Wed, 10 Aug 2011 23:00:00 +0100

CONCLUSIONS: Compared with patients treated with ADs and aripiprazole, those treated with ADs and olanzapine or quetiapine had greater utilization and higher expenditures. PMID: 21840058 [PubMed - as supplied by publisher] (Source: Clinical Therapeutics)

Aripiprazole/desvenlafaxine: Diabetic ketoacidosis and hyperglycaemia (first report with desvenlafaxine): 2 case reports

Reactions — Wed, 10 Aug 2011 17:36:32 +0100

(Source: Reactions)

Aripiprazole induced transient myopia: A case report and review of literature.

Cutaneous and Ocular Toxicology — Tue, 09 Aug 2011 23:00:00 +0100

We report a case of transient myopia in a 33-year-old male who was being treated for schizophrenia with oral quetiapine and was recently supplemented with aripiprazole. One month after the addition of aripiprazole the patient reported sudden onset painless blurring of vision in both eyes. He was found to have myopia of-3.0 diopters in both eyes; his corrected visual acuity being 20/20. He was advised to discontinue aripiprazole. Ten days later on examination, the patient had an uncorrected visual acuity of 20/20 in both eyes. The stoppage of symptoms on stopping the drug indicates a strong correlation between the drug and the adverse effect. Ophthalmologists and psychiatrists must be aware of this reversible adverse drug reaction, so it may be treated promptly. PMID: 21830909 [PubMed -...

Young Mania Rating Scale Line Item Analysis in Pediatric Subjects with Bipolar I Disorder Treated with Aripiprazole in a Short-Term, Double-Blind, Randomized Study

Journal of Child and Adolescent Psychopharmacology — Mon, 08 Aug 2011 16:51:02 +0100

Journal of Child and Adolescent Psychopharmacology , Vol. 0, No. 0. (Source: Journal of Child and Adolescent Psychopharmacology)

An Open-Label Study of Aripiprazole in Children with a Bipolar Disorder

Journal of Child and Adolescent Psychopharmacology — Mon, 08 Aug 2011 16:50:58 +0100

Journal of Child and Adolescent Psychopharmacology , Vol. 0, No. 0. (Source: Journal of Child and Adolescent Psychopharmacology)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE)

European Archives of Psychiatry and Clinical Neuroscience — Tue, 02 Aug 2011 05:52:36 +0100

This study also included a small descriptive arm in which patients could also be randomized to aripiprazole. Results of this exploratory analysis are described here. Clinically stable adults with schizophrenia or schizoaffective disorder previously treated with oral risperidone, olanzapine, or an oral conventional antipsychotic were randomized to RLAI or aripiprazole. Efficacy and tolerability were monitored for up to 24 months. A total of 45 patients were treated with aripiprazole (10–30 mg/day) and 329 patients with RLAI (25–50 mg i.m. every 2 weeks). Relapse occurred in 27.3% (95% CI: 15.0–42.8%) of aripiprazole-treated and 16.5% (95% CI: 12.7–21.0%) of RLAI-treated patients. Kaplan–Meier estimates of mean (standard error) relapse-free period were 313...

Early detection and management of atypical neuroleptic malignant syndrome secondary to aripiprazole

Schizophrenia Research — Mon, 01 Aug 2011 04:00:00 +0100

Neuroleptic malignant syndrome (NMS) occurs in approximately 0.1% of hospitalized patients treated with antipsychotics () and is a lethal idiosyncratic reaction with a mortality rate of greater than10% (). A typical diagnosis of NMS requires core symptoms of hyperthermia and muscle rigidity, while the concept of atypical NMS associated with atypical antipsychotic treatment remains controversial (). For example, diaphoresis as the main manifestation is seen in 37.5% of aripiprazole cases (). Here, we report a case of aripiprazole-related atypical NMS with early detection and treatment. (Source: Schizophrenia Research)

Evidence-Based Recommendations for Monitoring Safety of Second Generation Antipsychotics in Children and Youth.

Journal of the Canadian Academy of Child and Adolescent Psychiatry — Sun, 31 Jul 2011 23:00:00 +0100

CONCLUSION: Multiple randomized controlled trials (RCTs) have established the efficacy of many of the SGAs in pediatric mental health disorders. These benefits however do not come without risk; both metabolic and neurological side effects occur in children treated with these SGAs. The risk of weight gain, increased BMI and abnormal lipids appears greatest with olanzapine, followed by clozapine and quetiapine. The risk of neurological side effects of treatment appears greatest with risperidone, olanzapine and aripiprazole. Appropriate monitoring procedures for adverse effects will improve the quality of care of children treated with these medications. PMID: 21804853 [PubMed - as supplied by publisher] (Source: Journal of the Canadian Academy of Child and Adolescent Psychiatry)

High Dosage of Aripiprazole Induced Priapism: A Case Report.

CNS Spectrums — Sun, 31 Jul 2011 23:00:00 +0100

Authors: Hsu WY, Chiu NY, Wang CH, Lin CY PMID: 21819800 [PubMed - as supplied by publisher] (Source: CNS Spectrums)

Pathological gambling and the treatment of psychosis with aripiprazole: case reports [Short reports]

The British Journal of Psychiatry — Sat, 30 Jul 2011 23:00:00 +0100

This paper details three case reports that suggest that pathological gambling activity may have been adversely modified following treatment for psychosis with the antipsychotic aripiprazole. These reports are discussed in the context of previous observations of the potential impact of aripiprazole on impulse control and the implications such observations could have for clinical practice and future research. (Source: The British Journal of Psychiatry)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D(2) and D(3) receptors.

European Journal of Pharmacology — Thu, 28 Jul 2011 23:00:00 +0100

Authors: Tadori Y, Forbes RA, McQuade RD, Kikuchi T Aripiprazole is the first dopamine D(2)/D(3) receptor partial agonist successfully developed and ultimately approved for treatment of a broad spectrum of psychiatric and neurological disorders. Aripiprazole's dopamine D(2) and serotonin 5-HT(1A) receptor partial agonist activities have been postulated to confer clinical efficacy without marked sedation, and a relatively favorable overall side-effect profile. Using aripiprazole's unique profile as a benchmark for new dopamine partial agonist development may facilitate discovery of new antipsychotics. We conducted an in vitro comparative analysis between aripiprazole, and its human metabolite OPC-14857 (7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl)butoxy)-2(1H)-quinolinone)); RGH-188 (tra...

Aripiprazole augmentation strategy in clomipramine-resistant depressive patients: An open preliminary study

European Neuropsychopharmacology — Mon, 25 Jul 2011 04:00:00 +0100

Abstract: Recent evidence supports the use of second generation antipsychotics in drug resistant depression. The aim of the present open-label study was to evaluate the effect of aripiprazole as an add-on medication in drug-resistant depressed patients who had not responded to clomipramine. Thirty-five patients with major depressive disorder (MDD) were included in the study. All patients had not responded to a previous adequate treatment with an SSRI and had been receiving clomipramine (daily doses ranging from 100 to 300mg) for 113.9±18.9days without getting significant clinical improvement. Aripiprazole was added at the fixed dose of 5mg/day and clinical status as well as clomipramine plasma levels were monitored before and after 4, 8, and 24weeks of combined treatment. Hamilton depress...

Aripiprazole: Hyperglycaemia progressing to diabetic ketoacidosis: case report

Reactions — Wed, 20 Jul 2011 16:58:58 +0100

(Source: Reactions)

Pharmacotherapy of Borderline Personality: Medicine or Mayhem

Psychology Today Personality Center — Mon, 18 Jul 2011 00:00:36 +0100

When are medications helpful in treating Borderline Personality?read more (Source: Psychology Today Personality Center)

A Randomized Trial Examining the Effectiveness of Switching From Olanzapine, Quetiapine, or Risperidone to Aripiprazole to Reduce Metabolic Risk: Comparison of Antipsychotics for Metabolic Problems (CAMP).

The American Journal of Psychiatry — Sun, 17 Jul 2011 23:00:00 +0100

MedWorm Sponsor Message: Find the best January Sales in the UK.

Disseminated eruption of ectopic sebaceous glands following Stevens-Johnson syndrome

Journal of the American Academy of Dermatology — Sat, 16 Jul 2011 16:19:58 +0100

To the Editor: An 18-year-old white woman presented with a 1-year history of numerous asymptomatic, yellowish and skin-colored papules and plaques diffusely involving her face and chest. She reported that these lesions had developed approximately 4 months after an episode of lamotrigine-induced Stevens-Johnson syndrome (SJS). She had received only supportive care during her hospitalization for SJS; she had not received skin grafts to the face or chest. The patient was otherwise healthy except for history of a mood disorder, which was well controlled with bupropion and aripiprazole. She also periodically used eye drops (loteprednol and cyclosporine) for chronic eye irritation secondary to SJS. (Source: Journal of the American Academy of Dermatology)

Aripiprazole: Parkinsonism: case report

Reactions — Wed, 13 Jul 2011 16:51:36 +0100

(Source: Reactions)

Patterns and Trends in Antipsychotic Prescribing for Parkinson Disease Psychosis [Original Contribution]

Archives of Neurology — Sun, 10 Jul 2011 23:00:00 +0100

Conclusions Half of the patients with PD and psychosis receive APs, not uncommonly high-potency agents associated with worsening parkinsonism, and frequency of use has been unchanged since the "black box" warning for AP use in patients with dementia was issued. Recent trends are a shift to quetiapine use and the common use of aripiprazole. As psychosis and dementia are frequently comorbid in PD, safety risks associated with AP use in this population need to be assessed. (Source: Archives of Neurology)

The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine

European Journal of Clinical Pharmacology — Fri, 08 Jul 2011 06:36:26 +0100

Conclusions There were marked differences in the degree of influence of paroxetine coadministration on the pharmacokinetics of aripiprazole between CYP2D6 EMs and IMs, but no apparent differences were found between two CYP2D6 genotypes in fluvoxamine coadministration. Aripiprazole can be used safely in combination with SSRIs that have a CYP enzyme-inhibitory action. Content Type Journal ArticlePages 1-9DOI 10.1007/s00228-011-1094-4Authors Junichi Azuma, Clinical Pharmacology and Pharmacogenomics, Department of Pharmacy, School of Pharmacy, Hyogo University of Health Sciences, 1-3-6, Minatojima, Chuo-ku, Kobe, 650–8530 JapanTomoko Hasunuma, Research Center for Clinical Pharmacology, Kitasato University, 5-9-1, Shirokane, Minato-ku, Tokyo, 108–0072 JapanMasanori K...

Antipsychotic drugs may affect children's adiposity and insulin sensitivity

Modern Medicine Contemporary Pediatrics — Thu, 07 Jul 2011 23:00:00 +0100

Aripiprazole, olanzapine, and risperidone appear to increase body fat and change insulin sensitivity in children being treated for disruptive behavior disorders, according to new research presented at the meeting of the American Diabetes Association meeting in San Diego. (Source: Modern Medicine Contemporary Pediatrics)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

PA.10 Tolerability profile of Aripiprazole in adult patients with Tourette syndrome

Journal of Neurology, Neurosurgery and Psychiatry — Wed, 06 Jul 2011 23:00:00 +0100

Conclusions The most commonly reported adverse effects of Aripiprazole treatment in TS were sedation and sleep problems. In the majority of cases, adverse effects were not severe. In our clinical sample there were no predictors for poor tolerability. Slow titration is recommended in order to minimise the occurrence of adverse effects. (Source: Journal of Neurology, Neurosurgery and Psychiatry)

PA.14 Atypical antipsychotics for Tourette syndrome

Journal of Neurology, Neurosurgery and Psychiatry — Wed, 06 Jul 2011 23:00:00 +0100

Conclusions It is difficult to draw clear conclusions from the identified trials in the review as evidence is limited. Placebo controlled trials with longer duration and larger groups are needed to investigate the safety and efficacy of atypical antipsychotics as a pharmaceutical class in TS populations. (Source: Journal of Neurology, Neurosurgery and Psychiatry)

Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome

Neurological Sciences — Wed, 06 Jul 2011 05:55:21 +0100

This study assessed the cardiovascular safety of the newer antipsychotic aripiprazole in comparison with the neuroleptic pimozide among young patients affected by TS. Fifty patients aged 6–18 years were assigned to either pimozide (n = 25; mean daily dose 4.4 mg/die) or aripiprazole (n = 25; 5.3 mg/die) treatment for up to 24 months. All patients underwent five serial cardiovascular assessments (baseline, 6, 12, 18 and 24 months). The group treated with pimozide showed significant changes in blood pressure (decreased), QT and QTc (both prolonged). The aripiprazole group showed changes from baseline to peak values in blood pressure (increased), whilst modifications in QT and QTc were not statistically significant. At equivalent doses, arip...

Recent Advances in the Treatment of Borderline Personality Disorder.

Current Medicinal Chemistry — Sun, 03 Jul 2011 23:00:00 +0100

This article reviews double-blind randomized controlled trials comparing active drugs versus placebo and drugs versus drugs, published between 1990 and 2010 and focused on the treatment of borderline personality disorder. Different classes of psychoactive agents, such as antipsychotics, mood stabilizers, antidepressants, and dietary supplementation were tested in BPD patients. More recent evidences suggest that mood stabilizers (topiramate, valproate and lamotrigine), second generation antipsychotics (olanzapine and aripiprazole) and omega-3 fatty acids can be useful to treat affective symptoms and impulsive-behavioural dyscontrol in BPD patients. Moreover, antipsychotics significantly improve cognitive symptoms in patients with BPD. SSRIs were found effective in decreasing severity of dep...

Alkermes Announces Positive Results From Clinical Study Of ALKS 9070 For Treatment Of Schizophrenia

Health News from Medical News Today — Fri, 01 Jul 2011 16:00:00 +0100

Alkermes, Inc. (NASDAQ: ALKS) today announced positive topline results from a phase 1b, double-blind, randomized, placebo-controlled study of ALKS 9070 in patients with schizophrenia. ALKS 9070, a proprietary Alkermes molecule for the treatment of schizophrenia, is designed to provide patients with once-monthly dosing of a medication that, once in the body, converts into aripiprazole, a molecule that is commercially available under the name ABILIFY® for the treatment of a number of central nervous system (CNS) disorders... (Source: Health News from Medical News Today)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Influence of aripiprazole on the antidepressant, anxiolytic and cognitive functions of rats.

Pharmacological Reports — Fri, 01 Jul 2011 04:00:00 +0100

Authors: Burda K, Czubak A, Kus K, Nowakowska E, Ratajczak P, Zin J Abstract Recent research has suggested that cognitive disorders are a persistent trait of mental illnesses such as schizophrenia. Cognitive deficits in the course of schizophrenia may be due to the disease and/or drug therapy, especially with old-generation drugs. Several clinical experiments have indicated the beneficial effects of new-generation antipsychotics on cognitive processes in patients treated for mental disorders. Aripiprazole is a new, atypical antipsychotic with a unique mechanism of action, which may have positive effects on cognitive functions. The aim of this study was to investigate the effects of aripiprazole on spatial memory in the Morris water maze and antidepressant activity in the Porsolt te...

Aripiprazole: Neuroleptic malignant syndrome: case report

Reactions — Sat, 18 Jun 2011 16:44:29 +0100

(Source: Reactions)

Aripiprazole-Related Body-Weight Gain and Nutritional Counseling [LETTERS TO THE EDITOR]

J Neuropsychiatry Clin Neurosci — Tue, 14 Jun 2011 23:00:00 +0100

(Source: J Neuropsychiatry Clin Neurosci)

Combination Loxapine and Aripiprazole for Refractory Hallucinations in Schizophrenia (July/August).

The Annals of Pharmacotherapy — Mon, 13 Jun 2011 23:00:00 +0100

CONCLUSIONS The combination of aripiprazole and high-dose loxapine should be considered in patients with schizophrenia who develop treatment-refractory hallucinations, particularly those who are unwilling to accept treatment with either depot antipsychotics or clozapine. PMID: 21672885 [PubMed - as supplied by publisher] (Source: The Annals of Pharmacotherapy)

Aripiprazole/fluoxetine interaction: Leucopenia: case report

Reactions — Mon, 13 Jun 2011 16:21:55 +0100

(Source: Reactions)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Clozapine: Obsessive-compulsive symptoms treated with aripiprazole: 2 case reports

Reactions — Mon, 13 Jun 2011 16:21:55 +0100

(Source: Reactions)

Could maternal perinatal atypical antipsychotic treatments program later metabolic diseases in the offspring?

European Journal of Pharmacology — Sat, 11 Jun 2011 23:00:00 +0100

Authors: Guillemot J, Laborie C, Dutriez-Casteloot I, Maron M, Deloof S, Lesage J, Breton C, Vieau D An association is established between schizophrenia and the development of metabolic alterations including cardiovascular diseases, type 2 diabetes and obesity. Perinatal insults, such as undernutrition, have been shown to increase the propensity to develop these pathologies, reinforcing the idea that schizophrenia may have a neurodevelopmental origin. Moreover, the use of second generation antipsychotics (SGAs) also known as "atypical" neuroleptics has also been demonstrated to exacerbate metabolic anomalies in patients with schizophrenia. SGAs are able to cross the placental barrier and have been detected in milk from women receiving atypical neuroleptics treatment during the perinata...

Aripiprazole in the Treatment of Irritability in Pediatric Patients (Aged 6–17 Years) with Autistic Disorder: Results from a 52-Week, Open-Label Study

Journal of Child and Adolescent Psychopharmacology — Fri, 10 Jun 2011 18:58:20 +0100

Journal of Child and Adolescent Psychopharmacology Jun 2011, Vol. 21, No. 3: 229-236. (Source: Journal of Child and Adolescent Psychopharmacology)

Clomipramine, but not haloperidol or aripiprazole, inhibits quinpirole-induced water contrafreeloading, a putative animal model of compulsive behavior

Psychopharmacology — Fri, 10 Jun 2011 06:33:25 +0100

Conclusions CIM reinstates control patterns of drinking, while HAL and ARI where partially or not effective at all, respectively. As far as CIM is considered a first line treatment in OCD, these results further strengthen the notion that QNP-induced CFL belongs to the realm of dopaminergic drug-induced compulsive behaviors. Content Type Journal ArticlePages 1-11DOI 10.1007/s00213-011-2372-7Authors Lorenza De Carolis, Department of Physiology and Pharmacology “Vittorio Erspamer”, Sapienza University of Rome, Italy, 5 Piazzale Aldo Moro, 00185 Rome, ItalyChiara Schepisi, Department of Physiology and Pharmacology “Vittorio Erspamer”, Sapienza University of Rome, Italy, 5 Piazzale Aldo Moro, 00185 Rome, ItalyMichele S. Milella, Department of Physiology and Pharm...

Company-led drug recall: Abilify tablets parallel distributed by Chemilines Limited

NeLM - News — Mon, 06 Jun 2011 23:00:00 +0100

Source: MHRA Area: News The MHRA has posted details of a company-led drug recall on its website, for the following product: . Abilify 5, 10, 15 and 30mg tablets (distributed by Chemilines); multiple batches released between 1st June 2010 and 3rd February 2011 The recall has been initiated due to a failure to update patient information leaflet to include updated information on administration and safety warnings, including warning on risk of venous thromboembolism which is mandatory and was initiated by the European Medicines Agency. It is expected that very little stock will remain in the supply chain. The updated leaflet has been included in packs since February 2011. Please see the link below for further details. (Source: NeLM - News)

MedWorm Sponsor Message: Find the best January Sales in the UK.

The Brown University Psychopharmacology Update — Mon, 06 Jun 2011 21:46:16 +0100

AbstractMixed Results for Aripiprazole Augmentation in Nonresponders to ClozapineBupropion Effective for Treating Excessive Online Gaming and Comorbid DepressionInfluence of Smoking Ban on Clozapine and Norclozapine ConcentrationsAdjunctive Aripiprazole in Treatment‐Resistant Bipolar I DisorderGenetic Screening for Carbamazepine‐Induced Hypersensitivity and Toxic EffectsRisk of Suicidal Ideation with SSRI or PsychotherapyScarce Evidence for Memantine Efficacy in Mild‐to‐Moderate ADHaloperidol for Charles Bonnet Syndrome and Comorbid Cerebellar InfarctionNew Approvals (Source: The Brown University Psychopharmacology Update)

Risperdal Manufacturer Guilty of Bad Marketing, Huge Fine Ordered

About.com Bipolar Disorder — Sun, 05 Jun 2011 23:00:00 +0100

Back in 2004 I reported that Janssen Pharmaceuticals, manufacturer of Risperdal, had admitted to making misleading claims about the drug's safety and effectiveness. Risperdal - generic name risperidone - is an atypical antipsychotic that may be used to treat bipolar disorder. At the time, Janssen (a subsidiary of Johnson & Johnson) said it was notifying doctors about the misleading information that had initially been released with Risperdal. In March, though, Johnson & Johnson was found guilty of "engaging in unfair or deceptive acts" in a court case in South Carolina based on a marketing letter sent to physicians in November 2003, about seven months before the admission, and has now been ordered to pay fines totaling $327 million to the State of South Carolina alone. J&J h...

Analgesics abuse: Medication overuse headache treated with aripiprazole: case report

Reactions — Sun, 05 Jun 2011 19:54:23 +0100

(Source: Reactions)

Aripiprazole: Restless legs syndrome: case report

Reactions — Sun, 05 Jun 2011 19:54:23 +0100

(Source: Reactions)

Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers

Psychopharmacology — Sat, 04 Jun 2011 06:01:31 +0100

Conclusion Antidopaminergic modulation in healthy subjects induced substantial impairments in several domains of subjective well-being. In particular an association between hypodopaminergic states and depressive symptoms was observed which may be amplified by a genetic predisposition. Content Type Journal ArticlePages 1-16DOI 10.1007/s00213-011-2368-3Authors Tanja Veselinović, Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Pauwelsstrasse 30, 52074 Aachen, GermanyHolger Schorn, Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Pauwelsstrasse 30, 52074 Aachen, GermanyIngo Vernaleken, Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Pauwelsstrasse 30, 52074 Aachen...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Anti-aversive effects of the atypical antipsychotic, aripiprazole, in animal models of anxiety

Journal of Psychopharmacology — Tue, 31 May 2011 23:00:00 +0100

Aripiprazole is a unique antipsychotic that seems to act as a partial agonist at dopamine D2-receptors, contrasting with other drugs in this class, which are silent antagonists. Aripiprazole may also bind to serotonin receptors. Both neurotransmitters may play major roles in aversion-, anxiety- and panic-related behaviours. Thus, the present work tested the hypothesis that this antipsychotic could also have anti-aversive properties. Male Wistar rats received injections of aripiprazole (0.1–10 mg/kg) and were tested in the open field, in the elevated plus and T mazes (EPM and ETM, respectively) and in a contextual fear conditioning paradigm. Aripiprazole (1 mg/kg) increased the percentage of entries onto the open arms of the EPM and attenuated escape responses in the ETM. In the latte...

Low‐dose aripiprazole resolved complex hallucinations in the left visual field after right occipital infarction (Charles Bonnet syndrome)

Psychogeriatrics — Tue, 31 May 2011 23:00:00 +0100

We reported a patient who suffered from complex visual hallucinations with left homonymous hemianopsia. Brain imaging showed an acute haemorrhage infarct at the right occipital lobe. Charles Bonnet syndrome (CBS) was suspected and aripiprazole was prescribed at 5 mg daily. After 3 weeks, the symptoms of hallucinations and anxiety were relieved. Although some CBS patients might be self‐limited without discomfort, low‐dose aripiprazole can be considered as a safe medication for significantly anxious patients with CBS. (Source: Psychogeriatrics)

Aripiprazole: Affective disorders, cognitive disorders and extrapyramidal symptoms: case report

Reactions — Mon, 30 May 2011 16:35:06 +0100

(Source: Reactions)

Aripiprazole and haloperidol in the treatment of delirium.

The Australian and New Zealand Journal of Psychiatry — Fri, 27 May 2011 19:33:39 +0100

Conclusion: From our secondary analysis, aripiprazole may be as effective as haloperidol in the management of delirium and its subtypes. Treatment with haloperidol resulted in more side effects. PMID: 21563866 [PubMed - in process] (Source: The Australian and New Zealand Journal of Psychiatry)

Metabolic effects and cost‐effectiveness in aripiprazole versus olanzapine in schizophrenia and bipolar disorder

Acta Psychiatrica Scandinavica — Thu, 26 May 2011 02:56:39 +0100

Conclusion: The significantly lower risk of developing metabolic syndrome observed with aripiprazole compared with olanzapine is associated with less risk of diabetes and cardiovascular morbidity and mortality that translates into lower overall treatment cost and improved quality of life over time. (Source: Acta Psychiatrica Scandinavica)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Switching to Aripiprazole May Reduce Metabolic Risk

Medscape Today Headlines — Wed, 25 May 2011 22:44:00 +0100

A new randomized trial shows that switching from the antipsychotics olanzapine, quetiapine, or risperidone to aripiprazole may improve metabolic measures in schizophrenic patients. Medscape Medical News (Source: Medscape Today Headlines)

Metabolic effects and cost‐effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder

Acta Psychiatrica Scandinavica — Mon, 23 May 2011 23:00:00 +0100

Geodon is Found Less Effective for Obese, Hyperglycemic Bipolars

About.com Bipolar Disorder — Mon, 23 May 2011 15:51:47 +0100

Geodon (ziprasidone), an atypical antipsychotic often prescribed for patients with bipolar disorder, is far less likely to be effective in patients with a BMI of 28.8 or higher and/or a blood glucose level of 140mg/dL or higher (see What Your Blood Glucose Test Results Mean). What makes this news especially notable is that it came from a study funded by Pfizer, Geodon's manufacturer. The study of 267 acutely manic patients over 3 weeks found that patients with a BMI below 28.8 were quite a bit more likely to respond to Geodon than their obese counterparts. And the difference was particularly dramatic regarding the blood sugar threshold - only 16% of patients with the higher glucose level responded to Geodon, while more than half of those with the lower level responded. Ironically, Geodon...

Aripiprazole [Abilify] will be reimbursed in British Columbia through BC PharmaCare from 26 April 2011

PharmacoEconomics and Outcomes News — Thu, 19 May 2011 18:17:31 +0100

(Source: PharmacoEconomics and Outcomes News)

Aripiprazole: Pathological gambling: 2 case reports

Reactions — Wed, 18 May 2011 17:09:57 +0100

(Source: Reactions)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Aripiprazole/haloperidol: Increased rigidity and bradykinesia: case report

Reactions — Wed, 18 May 2011 17:09:57 +0100

(Source: Reactions)

Change in Level of Productivity in the Treatment of Schizophrenia with Olanzapine or Other Antipsychotics

BMC Psychiatry - Latest articles — Mon, 16 May 2011 23:00:00 +0100

Background: : When treating schizophrenia, improving patients' productivity level is a major goal considering schizophrenia is a leading cause of functional disability. Productivity level has been identified as the most preferred treatment outcome by patients with schizophrenia. However, little has been done to systematically investigate productivity levels in schizophrenia. We set out to better understand the change in productivity level among chronically ill patients with schizophrenia treated with olanzapine compared with other antipsychotic medications. We also assessed the links between productivity level and other clinical outcomes.MethodS: This post hoc analysis used data from 6 randomized, double-blind clinical trials of patients with schizophrenia or schizoaffective disorder, with...

Aripiprazole Augmentation in the Treatment of Military-Related PTSD with Major Depression: a retrospective chart review

BMC Psychiatry - Latest articles — Mon, 16 May 2011 23:00:00 +0100

Background: In this chart review, we attempted to evaluate the benefits of adding aripiprazole in veterans with military-related PTSD and comorbid depression, who had been minimally or partially responsive to their existing medications. Methods: A retrospective chart review of patients who received an open-label, flexible-dose, 12- week course of adjunctive aripiprazole was conducted in 27 military veterans meeting DSM-IV criteria for PTSD and comorbid major depression. Concomitant psychiatric medications continued unchanged, except for other antipsychotics which were discontinued prior to initiating aripiprazole. The primary outcome variable was a change from baseline in the PTSD checklist-military version (PCL-M) and the Beck Depression Inventory (BDI-II). Results: PTSD severity (Total P...

The GiSAS study: Rationale and design of a pragmatic randomized controlled trial on aripiprazole, olanzapine and haloperidol in the long-term treatment of schizophrenia

Contemporary Clinical Trials — Sun, 15 May 2011 23:00:00 +0100

Abstract: Given the controversy about the comparative efficacy of first- compared with second-generation antipsychotics in the treatment of schizophrenia, more large-scale evidence is needed to guide clinicians in their prescriptions. Most randomized controlled trials (RCTs) were conducted in centers of excellence on highly selected samples, poorly representative of real-world patients, and often suffered conflicts of interest as they were sponsored by drug companies.The primary aim of the present study is to compare the effectiveness of haloperidol, olanzapine and aripiprazole in a representative sample of schizophrenia patients. The GiSAS trial is an open-label, independent, pragmatic RCT in Italian community-based public psychiatric services. At least 260 patients meeting the DSM-IV cri...

[Aripiprazole-induced parkinsonism in a 64-year-old female patient diagnosed with bipolar disorder.]

Tijdschrift voor Psychiatrie — Fri, 13 May 2011 04:00:02 +0100

Authors: de Schutter P, Bouckaert F, Peuskens J PMID: 21538299 [PubMed - as supplied by publisher] (Source: Tijdschrift voor Psychiatrie)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Aripiprazole: QTc interval prolongation: case report

Reactions — Wed, 11 May 2011 17:13:45 +0100

(Source: Reactions)

Memory disorders associated with drugs consumption: updating through a case / non‐case study in the French PharmacoVigilance Database

British Journal of Clinical Pharmacology — Mon, 09 May 2011 23:00:00 +0100

Conclusions Our study confirmed an association between memory disorders and some drugs like benzodiazepines or anticonvulsants. But other drugs like hypnotics “benzodiazepines‐like”, newer anticonvulsants, SRI antidepressants, isotretinoin and cyclosporine were significantly associated with memory disorders although it was not or poorly described in literature.Taking account of limits of this study in the FPVD (under‐reporting, notoriety bias …), the case/non‐case method allows to assess and detect associations between drugs exposure and a specific adverse drug reaction such as memory disorders, and could thus generate signals and orientate us to further prospective studies to confirm such associations. (Source: British Journal of Clinical Pharmacology)

Slim Evidence Supporting Drug as Bipolar Maintenance Therapy

Medscape Today Headlines — Mon, 09 May 2011 20:16:05 +0100

Despite widespread use of aripiprazole as a maintenance treatment for bipolar disorder, researchers found only a single trial on its use for this FDA-approved indication. Medscape Medical News (Source: Medscape Today Headlines)

Abilify Study Flawed, Say Researchers - Is Long-Term Use Appropriate?

About.com Bipolar Disorder — Mon, 09 May 2011 15:00:04 +0100

Abilify is an atypical antipsychotic that was originally approved (in 2002) to treat schizophrenia. In 2004 the drug was approved to treat acute manic and mixed episodes of bipolar disorder, and in 2005 the FDA approved Abilify for long-term maintenance therapy in bipolar disorder. Now Harvard University researchers say that the 2005 approval was based on a single clinical study that had serious flaws. Psychiatrist Alexander C. Tsai, M.D., one of the lead authors of the current review, said the methodology was biased in favor of Abilify and the study was too short to give credible information about long-term use. In addition, that single study was funded by the companies that developed and market Abilify. This does not mean you should stop taking Abilify immediately. Rapid withdrawal can...

Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: A review of the randomized controlled studies

European Neuropsychopharmacology — Sun, 08 May 2011 23:00:00 +0100

Abstract: In children and adolescents the Second Generation Antipsychotics (SGAs) represent the class of psychotropic drugs whose use has grown more significantly in recent years: they are primarily used for treatment of patients with disruptive behavior disorders, mood disorders and pervasive developmental disorders or mental retardation. In order to compare the efficacy and tolerability of antipsychotics against placebo or each other, a systematic Medline/PubMed search for randomized, double blind studies on SGA in patients younger than 18years of age at enrolment, was conducted. Papers on schizophrenia, discussed in another article of this specific issue, were excluded by the efficacy analysis. A set of standard efficacy and safety indices, such as treatment effect sizes (ES), the Numbe...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Happy Birthday, Dead Friend

Psychology Today Parenting Center — Fri, 06 May 2011 15:25:22 +0100

Today is my friend's birthday. I can't call her or send her a card or even email her, because she's dead. She glided gently from this world, according to the cops who found her body in the cottage where she swallowed too many prescription pills. I can't send her a birthday card. So, as usual, I Googled her. read more (Source: Psychology Today Parenting Center)

Aripiprazole: in the treatment of irritability associated with autistic disorder in pediatric patients.

Paediatric Drugs — Wed, 04 May 2011 08:15:07 +0100

Authors: Curran MP Aripiprazole is an atypical antipsychotic approved for the treatment of irritability associated with autistic disorder in pediatric patients aged 6-17 years. In two, randomized, double-blind, placebo-controlled studies in pediatric patients aged 6-17 years with irritability associated with autistic disorder, 8 weeks of treatment with aripiprazole 2-15 mg/day, compared with placebo, resulted in significant improvements in the Aberrant Behavior Checklist Irritability subscale score at endpoint (primary endpoint), and the mean Clinical Global Impression-Improvement score. Aripiprazole was generally well tolerated in this patient population in the two 8-week studies and a 52-week study, with most adverse events being mild to moderate in severity. Aripiprazole was assoc...

FDA approved Big Pharma drugs without effectiveness data

NaturalNews.com — Wed, 04 May 2011 04:18:12 +0100

(NaturalNews) Consumers constantly are told how complicated it is to get a new drug on the market. After all, researchers have to jump through all sorts of hoops to assure safety before new therapies are approved for the public, right?It turns out they may be missing some of those hoops or not jumping through some of the most important ones.In fact, huge red flags are being raised about how drugs are tested and approved in two new studies, including one just published in the May 4th issue of the Journal of the American Medical Association (JAMA).A case in point: it turns out that only about half of the new prescription medications pushed onto the market over the last decade had the proper data together for the U.S. Food and Drug Administration - yet the FDA approved them anyhow.The informa...

Aripiprazole in the maintenance treatment of bipolar disorder: critical review of the evidence

NeLM - News — Tue, 03 May 2011 23:00:00 +0100

Source: PLoS Medicine Area: News According to the results of a critical review of the evidence, a single study represents the entirety of the literature on the use of aripiprazole for the maintenance treatment of bipolar disorder. Treatment of bipolar disorder is divided into three phases: acute treatment lasting about 2 months to achieve remission, continuance treatment lasting from months 2 through 6 to prevent relapse, and long-term maintenance treatment to prevent recurrence. The authors note that second-generation antipsychotics have increasingly gained popularity for the short-term treatment of acute manic episodes in bipolar disorder; their promotion for the maintenance treatment of these patients is however a more recent phenomenon. The purpose of this resea...

Limitations of evidence base for prescribing aripiprazole in maintenance therapy of bipolar disorder

ScienceDaily Headlines — Tue, 03 May 2011 21:17:17 +0100

MedWorm Sponsor Message: Find the best January Sales in the UK.

Limitations Of The Evidence Base For Prescribing Aripiprazole In Maintenance Therapy Of Bipolar Disorder

Health News from Medical News Today — Tue, 03 May 2011 21:00:00 +0100

The evidence base for the prescribing of aripiprazole in maintenance treatment of bipolar disorder is limited to a single trial, sponsored by the manufacturer of aripiprazole, according to a rigorous appraisal of the evidence for its use led jointly by Alexander Tsai of Harvard University, Boston USA, and Nicholas Rosenlicht of the University of California San Francisco, USA... (Source: Health News from Medical News Today)

Aripiprazole in the Maintenance Treatment of Bipolar Disorder: A Critical Review of the Evidence and Its Dissemination into the Scientific Literature

PLoS Medicine — Mon, 02 May 2011 23:00:00 +0100

Conclusions A single trial by Keck et al. represents the entirety of the literature on the use of aripiprazole for the maintenance treatment of bipolar disorder. Although careful review identifies four critical limitations to the trial's interpretation and overall utility, the trial has been uncritically cited in the subsequent scientific literature. Please see later in the article for the Editors' Summary (Source: PLoS Medicine)

Aripiprazole in the Maintenance Treatment of Bipolar Disorder: A Critical Review of the Evidence and Its Dissemination into the Scientific Literature

PLoS Medicine — Mon, 02 May 2011 23:00:00 +0100

Aripiprazole associated hyponatraemia.

Rural Remote Health — Mon, 02 May 2011 23:00:00 +0100

Authors: Lecamwasam DL, Alexander J PMID: 21539435 [PubMed - as supplied by publisher] (Source: Rural Remote Health)

[Delusional parasitosis associated with dialysis treated with aripiprazole].

Acta Medica Portuguesa — Sun, 01 May 2011 04:00:00 +0100

We report the case of a 75-year-old Chinese lady that presented delusional parasitosis with visual hallucinations four months after starting peritoneal dialysis. This psychosis is characterized by the persistent and unshakable belief of being infested with small living organisms, although there is no medical evidence for this. The patient had no previous history of psychiatric disorders, presented diminished visual acuity due to cataracts and macular degeneration, did not show cognitive deterioration, and was medicated with erythropoietin. During the course of the psychosis she presented an episode of visual hallucinations possibly related to Charles Bonnet syndrome. After two months of treatment with aripiprazole the psychotic symptoms remitted considerably. Aripiprazole is a neuroleptic ...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

A Systematic Review of Medical Treatments for Children With Autism Spectrum Disorders

PEDIATRICS — Sat, 30 Apr 2011 23:00:00 +0100

CONCLUSIONS: Although many children with ASDs are currently treated with medical interventions, strikingly little evidence exists to support benefit for most treatments. Risperidone and aripiprazole have shown benefit for challenging and repetitive behaviors, but associated adverse effects limit their use to patients with severe impairment or risk of injury. (Source: PEDIATRICS)

High dosage of aripiprazole‐induced dysphagia

International Journal of Eating Disorders — Sat, 30 Apr 2011 23:00:00 +0100

Conclusion:Aripiprazole‐induced dysphagia is rare, and it is important to beaware that it does occur with high‐dosage treatment. © 2011 by Wiley Periodicals, Inc. (Int J Eat Disord 2011;) (Source: International Journal of Eating Disorders)

Current and Promising Pharmacotherapies, and Novel Research Target Areas in the Treatment of Alcohol Dependence: A Review.

Current Pharmaceutical Design — Wed, 27 Apr 2011 23:00:00 +0100

Authors: Edwards S, Kenna GA, Swift RM, Leggio L Harmful alcohol use is a risk factor in more than 60 diseases and injuries resulting in approximately 2.5 million deaths per year worldwide. In the United States (US) and Europe, there are only a few medications approved for alcohol dependence (AD) however, these medications have only been moderately effective and there is a crucial need for more effective treatments. This review briefly summarizes research on currently approved medications for AD, as well as promising medications like topiramate, baclofen and ondansetron. Topiramate is likely the most promising new treatment for AD, however, further research is needed to determine the optimal dose and appropriate length of treatment. Baclofen, a GABA(B) agonist, is a promising medicatio...

Aripiprazole and Ropinirole Treatment for Cocaine Dependence: Evidence from a Pilot Study.

Current Pharmaceutical Design — Wed, 27 Apr 2011 23:00:00 +0100

Conclusions: Our pilot study indicates that cocaine craving decreases with both aripiprazole and ropinirole treatment but aripiprazole is more efficacious in reducing cocaine use. PMID: 21524261 [PubMed - as supplied by publisher] (Source: Current Pharmaceutical Design)

MedWorm: Abilify

Aripiprazole: A Review of its Use in the Management of Schizophrenia in Adults

Aripiprazole may be free from tachyphylaxis: Preliminary findings

Table of Contents

A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy among Depressed Outpatients with Inadequate Response to Prior Antidepressant Therapy (ADAPT-A Study)

ABILIFY (Aripiprazole) Tablet [PD-Rx Pharmaceuticals, Inc.]

ABILIFY (Aripiprazole) Tablet [H.J. Harkins Company, Inc.]

Determination of aripiprazole in rat plasma and brain using ultra-performance liquid chromatography/electrospray ionization tandem mass spectrometry.

Aripiprazole: Pathological gambling: 3 case reports

Treatments for Methamphetamine Abuse: A Literature Review for the Clinician

In vitro effect of antipsychotics on brain energy metabolism parameters in the brain of rats

Striatal and extrastriatal dopamine D2 receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [11C]raclopride and [11C]FLB457

ABILIFY (Aripiprazole) Tablet [Physicians Total Care, Inc.]

Intermittent aripiprazole for schizophrenia

Aripiprazole: A Review of its Use in the Management of Mania in Adults with Bipolar I Disorder

Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons

Aripiprazole may be effective maintenance in young children with bipolar disorder

Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose?

ABILIFY (Aripiprazole) Tablet [Lake Erie Medical Surgical Supply DBA Quality Care Products LLC]

[Aripiprazole augmentation treatment in treatment resistant bipolar depression: two patient reports].

Discriminative stimulus, subject-rated and cardiovascular effects of cocaine alone and in combination with aripiprazole in humans

Reinforcement Learning and Gilles de la Tourette Syndrome: Dissociation of Clinical Phenotypes and Pharmacological Treatments [Original Article]

Aripiprazole plus divalproex for recently manic or mixed patients with bipolar I disorder: a 6‐month, randomized, placebo‐controlled, double‐blind maintenance trial

Aripiprazole: Delayed neurotoxicity in pediatric patients: 4 case reports

Aripiprazole: Tardive dyskinesia and tremor: case report

Aripiprazole altered plasma levels of brain‐derived neurotrophic factor and catecholamine metabolites in first‐episode untreated Japanese schizophrenia patients

Adjunctive aripiprazole for depression: predictive value of early assessment.

An open trial of aripiprazole for the treatment of delirium in hospitalized cancer patients.

Schizophrenia substance set for FDA review

Delusional Infestation in a Patient with Renal Failure, Metabolic Syndrome, and Chronic Cerebrovascular Disease Treated with Aripiprazole: A Case Report

Aripiprazole: Atypical neuroleptic malignant syndrome: case report

Aripiprazole: Hypersexuality: case report

ABILIFY (Aripiprazole) Tablet [Lake Erie Medical Surgical Supply DBA Quality Care Products LLC]

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Sign Historic Agreement to Deliver Innovative Medicines with Focus on Psychiatric Disorders Worldwide

Visible spectrophotometric method for the determination of aripiprazole in tablets

Memory disorders associated with consumption of drugs: updating through a case/noncase study in the French PharmacoVigilance Database

Discovery of {beta}-Arrestin-Biased Dopamine D2 Ligands for Probing Signal Transduction Pathways Essential for Antipsychotic Efficacy [Chemistry]

Aripiprazole: Hyponatraemia: case report

Improvement of tardive dyskinesia and dystonia associated with aripiprazole following a switch to quetiapine: case report and review of the literature

ABILIFY (Aripiprazole) Tablet [Cardinal Health]

Abilify 7.5 mg/ml solution for injection (intramuscular) (Aripriprazole)- Revised SPC

[Rapid tranquillisation; review of the literature and recommendations].

Aripiprazole in Children and Adolescents with Conduct Disorder: A Single-Center, Open-Label Study

Aripiprazole cost effective for teens with schizophrenia

[Articles] Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis

An Efficient Synthesis of Aripiprazole, Buspirone and NAN‐190 by the Reductive Alkylation of Amines Procedure

Effectiveness and safety of antipsychotics in early onset psychoses: A long-term comparison

Aripiprazole/loxapine: Tremor, sedation and sialorrhoea: 2 case reports

Aripiprazole/olanzapine/risperidone: Catatonia and neuroleptic malignant syndrome: case report

Aripiprazole monotherapy in the treatment of vascular parkinsonism

Meta-analysis: Efficacy and comparative effectiveness of atypical antipsychotics for off-label uses

Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in Adults: A Systematic Review and Meta-analysis [Clinical Review]

Coming Soon to an Entrepreneur Near You: The Cyclothymic Personality

Improvement of Oral Dyskinesia After Switching From Aripiprazole to Paliperidone: A Case Report [LETTERS TO THE EDITOR]

Aripiprazole-Associated Rhabdomyolysis in a Patient With Schizophrenia [LETTERS TO THE EDITOR]

Aripiprazole: Persistent hiccups: case report

Geissoschizine methyl ether has third-generation antipsychotic-like actions at the dopamine and serotonin receptors.

You Are Not "Chemically Imbalanced"!

Aripiprazole: Enuresis: case report

Psychiatric Medication Minimization Strategies: Part I

Addition of Aripiprazole to the Clozapine May Be Useful in Reducing Anxiety in Treatment-Resistant Schizophrenia

A prospective, multicentre, open-label study to evaluate the effectiveness of aripiprazole in the treatment of a broad range of patients with schizophrenia.

Clinical usefulness of second-generation antipsychotics in treating children and adolescents diagnosed with bipolar or schizophrenic disorders.

Aripiprazole Associated With Acute Dystonia, Akathisia, and Parkinsonism in a Single Patient.

Adherence, persistence of use, and costs associated with second-generation antipsychotics for bipolar disorder

Aripiprazole: Dizziness: case report

Aripiprazole: Tardive dyskinesia: case report

A Randomized Trial Examining the Effectiveness of Switching From Olanzapine, Quetiapine, or Risperidone to Aripiprazole to Reduce Metabolic Risk: Comparison of Antipsychotics for Metabolic Problems (CAMP) [Articles]

Adherence, Persistence of Use, and Costs Associated With Second-Generation Antipsychotics for Bipolar Disorder [Articles]

[Priapism due to a Single Dose of Quetiapine: A Case Report].

Aripiprazole in the Treatment of Irritability Associated with Autistic Disorder in Paediatric Patients: Profile Report

Aripiprazole versus placebo for schizophrenia

Aripiprazole: Parkinsonism in a child: case report

Aripiprazole monotherapy in the treatment of bipolar disorder: A meta-analysis

Aripiprazole versus placebo for schizophrenia.

Neurobehavioral and genotoxic parameters of antipsychotic agent aripiprazole in mice.

Aripiprazole Augmentation in the Treatment of Military-Related PTSD With Major DepressionAripiprazole Augmentation in the Treatment of Military-Related PTSD With Major Depression

Intent-to-Treat Analysis of Health Care Expenditures of Patients Treated With Atypical Antipsychotics as Adjunctive Therapy in Depression.

Aripiprazole/desvenlafaxine: Diabetic ketoacidosis and hyperglycaemia (first report with desvenlafaxine): 2 case reports

Aripiprazole induced transient myopia: A case report and review of literature.